{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:37:53Z","timestamp":1773297473995,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T00:00:00Z","timestamp":1180569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2007,10,17]]},"DOI":"10.1007\/s00259-007-0452-z","type":"journal-article","created":{"date-parts":[[2007,5,30]],"date-time":"2007-05-30T15:34:46Z","timestamp":1180539286000},"page":"1775-1782","source":"Crossref","is-referenced-by-count":55,"title":["Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT"],"prefix":"10.1007","volume":"34","author":[{"given":"Andreas K.","family":"Buck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Glatting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik","family":"Juweid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djurdja","family":"Tepsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas T. J.","family":"Vogg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Mattfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Neumaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven N.","family":"Reske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,31]]},"reference":[{"key":"452_CR1","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2002-07-2009","volume":"101","author":"M Sanchez-Beato","year":"2003","unstructured":"Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220\u201335.","journal-title":"Blood"},{"key":"452_CR2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"452_CR3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630\u20136.","journal-title":"J Clin Oncol"},{"key":"452_CR4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.1988.6.12.1832","volume":"6","author":"A Surbone","year":"1988","unstructured":"Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin\u2019s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988;6:1832\u20137.","journal-title":"J Clin Oncol"},{"key":"452_CR5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1259\/bjr.73.874.11271893","volume":"73","author":"AR Padhani","year":"2000","unstructured":"Padhani AR, Husband JE. Are current tumor response criteria relevant for the 21st century? Br J Radiol 2000;73:1031\u20133.","journal-title":"Br J Radiol"},{"key":"452_CR6","first-page":"1426","volume":"44","author":"AK Buck","year":"2003","unstructured":"Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: [18F]FLT versus [18F]FDG. J Nucl Med 2003;44:1426\u201331.","journal-title":"J Nucl Med"},{"key":"452_CR7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1023\/A:1011136324038","volume":"12","author":"M Sandherr","year":"2001","unstructured":"Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, et al. Pitfalls in imaging Hodgkin\u2019s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001;12:719\u201322.","journal-title":"Ann Oncol"},{"key":"452_CR8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1148\/rg.251045045","volume":"25","author":"T Kazama","year":"2005","unstructured":"Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005;25:191\u2013207.","journal-title":"Radiographics"},{"key":"452_CR9","first-page":"1633","volume":"29","author":"P Martiat","year":"1988","unstructured":"Martiat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin\u2019s lymphoma using positron emission tomography. J Nucl Med 1988;29:1633\u20137.","journal-title":"J Nucl Med"},{"key":"452_CR10","first-page":"1757","volume":"39","author":"AF Shields","year":"1998","unstructured":"Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998;39:1757\u201362.","journal-title":"J Nucl Med"},{"key":"452_CR11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/3337","volume":"4","author":"AF Shields","year":"1998","unstructured":"Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [18F]FLT and positron emission tomography. Nat Med 1998;4:1334\u20136.","journal-title":"Nat Med"},{"key":"452_CR12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/AAC.36.4.808","volume":"36","author":"XB Kong","year":"1992","unstructured":"Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3\u2032-fluoro-3\u2032-deoxythymidine and 3\u2032-azido-3\u2032-deoxythymidine. Antimicrob Agents Chemother 1992;36:808\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"452_CR13","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1016\/S0021-9258(18)68484-4","volume":"263","author":"JL Sherley","year":"1988","unstructured":"Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350\u20138.","journal-title":"J Biol Chem"},{"key":"452_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0065-2571(94)90006-X","volume":"34","author":"S Eriksson","year":"1994","unstructured":"Eriksson S, Arner E, Spasokoukotskaja T, Wang L, Karlsson A, Brosjo O, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul 1994;34:13\u201325.","journal-title":"Adv Enzyme Regul"},{"key":"452_CR15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s00259-002-0851-0","volume":"29","author":"U Seitz","year":"2002","unstructured":"Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3\u2032-[18F]fluoro-3\u2032-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29:1174\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR16","first-page":"1210","volume":"43","author":"JS Rasey","year":"2002","unstructured":"Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210\u20137.","journal-title":"J Nucl Med"},{"key":"452_CR17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00259-004-1611-0","volume":"32","author":"H Barthel","year":"2005","unstructured":"Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al. The uptake of 3\u2032-deoxy-3\u2032-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR18","first-page":"1688","volume":"43","author":"L Lu","year":"2002","unstructured":"Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B. Rat studies comparing 11C-FMAU, [18F]FLT, and [76Br]BFU as proliferation markers. J Nucl Med 2002;43:1688\u201398.","journal-title":"J Nucl Med"},{"key":"452_CR19","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/gut.52.11.1602","volume":"52","author":"DL Francis","year":"2003","unstructured":"Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602\u20136.","journal-title":"Gut"},{"key":"452_CR20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s00259-004-1462-8","volume":"31","author":"B Smyczek-Gargya","year":"2004","unstructured":"Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31:720\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR21","first-page":"226","volume":"45","author":"DC Cobben","year":"2004","unstructured":"Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer AJ, Hoekstra HJ, et al. [18F]FLT PET for visualization of laryngeal cancer: comparison with [18F]FDG PET. J Nucl Med 2004;45:226\u201331.","journal-title":"J Nucl Med"},{"key":"452_CR22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1158\/1078-0432.CCR-03-0040","volume":"10","author":"DC Cobben","year":"2004","unstructured":"Cobben DC, Elsinga PH, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL, et al. Detection and grading of soft tissue sarcomas of the extremities with [18F]-3\u2032-fluoro-3\u2032-deoxy-l-thymidine. Clin Cancer Res 2004;10:1685\u201390.","journal-title":"Clin Cancer Res"},{"key":"452_CR23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00259-004-1742-3","volume":"32","author":"SJ Choi","year":"2005","unstructured":"Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. [18F]3\u2032-deoxy-3\u2032-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR24","first-page":"945","volume":"46","author":"W Chen","year":"2005","unstructured":"Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with [18F]-FLT PET: comparison with [18F]-FDG. J Nucl Med 2005;46:945\u201352.","journal-title":"J Nucl Med"},{"key":"452_CR25","first-page":"400","volume":"46","author":"HL Westreenen van","year":"2005","unstructured":"van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005;46:400\u20134.","journal-title":"J Nucl Med"},{"key":"452_CR26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-003-1257-3","volume":"30","author":"H Dittmann","year":"2003","unstructured":"Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003;30: 1407\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR27","first-page":"3331","volume":"62","author":"AK Buck","year":"2002","unstructured":"Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, et al. 3-deoxy-3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331\u20134.","journal-title":"Cancer Res"},{"key":"452_CR28","first-page":"2681","volume":"63","author":"M Wagner","year":"2003","unstructured":"Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, et al. 3\u2032-[18F]fluoro-3\u2032-deoxythymidine ([18F]FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681\u20137.","journal-title":"Cancer Res"},{"key":"452_CR29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/1084978041979652","volume":"19","author":"I Buchmann","year":"2004","unstructured":"Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3\u2032-deoxy-3\u2032-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations\u2014a pilot study. Cancer Biother Radiopharm 2004;19:436\u201342.","journal-title":"Cancer Biother Radiopharm"},{"key":"452_CR30","first-page":"3315","volume":"8","author":"H Vesselle","year":"2002","unstructured":"Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 3\u2032deoxy-3\u2032-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315\u201323.","journal-title":"Clin Cancer Res"},{"key":"452_CR31","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1158\/0008-5472.CAN-06-1955","volume":"66","author":"AK Buck","year":"2006","unstructured":"Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66:11055\u201361.","journal-title":"Cancer Res"},{"key":"452_CR32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1023\/A:1010684101509","volume":"24","author":"HJ Machulla","year":"2000","unstructured":"Machulla HJ, Blocher A, Kuntzsch M. Simplified labeling approach for synthesizing 3\u2032-deoxy-3\u2032[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;24:843\u20136.","journal-title":"J Radioanal Nucl Chem"},{"key":"452_CR33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009113384","volume":"39","author":"NG Mikhaeel","year":"2000","unstructured":"Mikhaeel NG, Timothy AR, O\u2019Doherty MJ, Hain S, Maisey MN. [18F]FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin\u2019s lymphoma\u2014comparison with CT. Leuk Lymphoma 2000;39:543\u201353.","journal-title":"Leuk Lymphoma"},{"key":"452_CR34","first-page":"224","volume":"44","author":"L Kostakoglu","year":"2003","unstructured":"Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224\u201339.","journal-title":"J Nucl Med"},{"key":"452_CR35","first-page":"4464","volume":"91","author":"W Romer","year":"1998","unstructured":"Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin\u2019s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464\u201371.","journal-title":"Blood"},{"key":"452_CR36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00259-003-1120-6","volume":"30","author":"K Spaepen","year":"2003","unstructured":"Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [18F]FDG PET monitoring of tumor response to chemotherapy: does [18F]FDG uptake correlate with the viable tumor cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR37","first-page":"695","volume":"45","author":"A Waarde van","year":"2004","unstructured":"van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, et al. Selectivity of [18F]FLT and [18F]FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695\u2013700.","journal-title":"J Nucl Med"},{"key":"452_CR38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-004-1706-7","volume":"32","author":"AK Buck","year":"2005","unstructured":"Buck AK, Hetzel M, Schirrmeister H, Halter G, Moller P, Kratochwil C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005;32:525\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR39","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","volume":"100","author":"AL Rose","year":"2002","unstructured":"Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002;100:1765\u201373.","journal-title":"Blood"},{"key":"452_CR40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1634\/theoncologist.5-5-376","volume":"5","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 2000;5:376\u201384.","journal-title":"Oncologist"},{"key":"452_CR41","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1007\/s00259-002-0925-z","volume":"29","author":"H Dittmann","year":"2002","unstructured":"Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR42","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336\u201342.","journal-title":"Blood"},{"key":"452_CR43","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999\u20132007.","journal-title":"Blood"},{"key":"452_CR44","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1158\/0008-5472.CAN-04-4008","volume":"65","author":"J Leyton","year":"2005","unstructured":"Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3\u2032-deoxy-3\u2032-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202\u201310.","journal-title":"Cancer Res"},{"key":"452_CR45","first-page":"519","volume":"45","author":"N Oyama","year":"2004","unstructured":"Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45:519\u201325.","journal-title":"J Nucl Med"},{"key":"452_CR46","first-page":"1754","volume":"45","author":"M Sugiyama","year":"2004","unstructured":"Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, et al. Evaluation of 3\u2032-deoxy-3\u2032-[18F]-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754\u20138.","journal-title":"J Nucl Med"},{"key":"452_CR47","first-page":"114","volume":"46","author":"C Waldherr","year":"2005","unstructured":"Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3\u2032-deoxy-3\u2032-18F-fluorothymidine PET. J Nucl Med 2005;46:114\u201320.","journal-title":"J Nucl Med"},{"key":"452_CR48","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00259-005-1813-0","volume":"259","author":"AF Shields","year":"2005","unstructured":"Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of [18F]3\u2032-deoxy-3\u2032-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 2005;259:1269\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"452_CR49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.nucmedbio.2004.01.001","volume":"31","author":"JR Bading","year":"2004","unstructured":"Bading JR, Shahinian AH, Vail A, Bathija P, Koszalka GW, Koda RT, et al. Pharmacokinetics of the thymidine analogue 2\u2032-fluoro-5-methyl-1-beta-d-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nucl Med Biol 2004;31:407\u201318.","journal-title":"Nucl Med Biol"},{"key":"452_CR50","first-page":"1688","volume":"43","author":"L Lu","year":"2002","unstructured":"Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B. Rat studies comparing [11C]FMAU, [18F]FLT, and [76Br]BFU as proliferation markers. J Nucl Med 2002;43:1688\u201398.","journal-title":"J Nucl Med"},{"key":"452_CR51","doi-asserted-by":"crossref","first-page":"8558","DOI":"10.1158\/0008-5472.CAN-06-0898","volume":"66","author":"M Perumal","year":"2006","unstructured":"Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006;66:8558\u201364.","journal-title":"Cancer Res"},{"key":"452_CR52","doi-asserted-by":"crossref","first-page":"10104","DOI":"10.1158\/0008-5472.CAN-04-4297","volume":"65","author":"LM Kenny","year":"2005","unstructured":"Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104\u201312.","journal-title":"Cancer Res"},{"key":"452_CR53","first-page":"371","volume":"46","author":"M Muzi","year":"2005","unstructured":"Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3\u2032-deoxy-3\u2032-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005;46:371\u201380.","journal-title":"J Nucl Med"},{"key":"452_CR54","first-page":"274","volume":"46","author":"M Muzi","year":"2005","unstructured":"Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3\u2032-deoxy-3\u2032-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274\u201382.","journal-title":"J Nucl Med"},{"key":"452_CR55","first-page":"3791","volume":"63","author":"H Barthel","year":"2003","unstructured":"Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3\u2032-deoxy-3\u2032-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791\u20138.","journal-title":"Cancer Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-007-0452-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0452-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T10:19:40Z","timestamp":1628936380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-007-0452-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,31]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,10,17]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s00259-007-0452-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,31]]}}}